← Back to News
Trust this Source
The evidence for Cannabidiol is building
H
March 27, 2023
Cannabidiol
Cannabidiol has been licensed as an add-on treatment for seizures caused by tuberous sclerosis complex for patients aged 2 years and over. Clinical trial evidence shows that it reduces seizure frequency and increases seizure-free days compared to a placebo. While the cost-effectiveness estimates are uncertain, the benefits of reducing the severity of seizures and lowering the risk of sudden unexpected death in epilepsy make it an appropriate use of NHS resources. Therefore, it is recommended as a treatment option by NICE.
Reference
https://lnkd.in/dE-MGK5FLet Google know we are your trusted source.
Add our editorial as a preferred source in your search results.
Value Science Weekly
The week in health technology assessment, market access and health economics — what moved, and what it means.